Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
28 Marzo 2024 - 2:05PM
Business Wire
- Celebrating Amneal’s recent listing on the Nasdaq Stock
Exchange
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the
“Company”), a global pharmaceutical company, today announced that
Chirag and Chintu Patel, Co-founders and Co-Chief Executive
Officers, will ring the Nasdaq closing bell on Tuesday, April 2,
2024.
“As entrepreneurs who founded Amneal in 2002, we are pleased to
join the esteemed roster of Nasdaq-listed companies. Today Amneal
is a growing global pharmaceutical leader with a diverse portfolio
of essential medicines that help make healthy possible. Our focus
on patient access and affordability allows us to improve countless
lives, and our commitment to innovation and quality enables us to
create significant value for all our stakeholders. We thank the
entire Amneal family for their tremendous dedication and commitment
to those we serve, and we are excited for our next era of growth
and success,” said Chirag and Chintu Patel.
A live stream of the event is available at:
www.nasdaq.com/marketsite/bell-ringing-ceremony.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in
Bridgewater, NJ, is a global pharmaceutical company. We make
healthy possible through the development, manufacturing, and
distribution of a diverse portfolio of over 270 pharmaceutical
products, primarily within the United States. In its Generics
segment, the Company is expanding across a broad range of complex
product categories and therapeutic areas, including injectables and
biosimilars. In its Specialty segment, Amneal has a growing
portfolio of branded pharmaceuticals focused primarily on central
nervous system and endocrine disorders, with a pipeline focused on
unmet needs. Through its AvKARE segment, the Company is a
distributor of pharmaceuticals and other products for the U.S.
federal government, retail, and institutional markets. For more
information, please visit www.amneal.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240328005176/en/
Amneal Contact Anthony DiMeo Head of Investor Relations
anthony.dimeo@amneal.com
Amneal Pharmaceuticals (NYSE:AMRX)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Amneal Pharmaceuticals (NYSE:AMRX)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024